Recurrent Pancreatic Carcinoma Active Not Recruiting Phase 1 Trials for Erlotinib (DB00530)

Also known as: Pancreatic carcinoma recurrent / Pancreas carcinoma recurrent / Pancreatic cancer recurrent

IndicationStatusPhase
DBCOND0043478 (Recurrent Pancreatic Carcinoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00878163GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryTreatment
NCT01660971Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryTreatment